Figure 1
![Figure 1. TFS of 449 patients with CLL according to the sFLC assay. Kaplan-Meier curves show the 3-year probability of remaining treatment-free for CLL cases subdivided into 3 groups based on their normal [normal sFLC(κ/λ)] or abnormal κ or λ sFLC ratio. The 3-year TFS was significantly lower in patients with κ or λ sFLC(κ/λ).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/24/10.1182_blood-2011-04-345587/4/zh89991182680001.jpeg?Expires=1735807605&Signature=xcW0XcoNXFTHrxBiEiFt6K36BOOq4qZShkfWREaDe18VfDbzrBCEP37FZItMF0C~KUn-ZmRwOWN3ScYFXo1IN06M2LJsMzGeH4oeW-yCDgBjWlonclzoeqPHJtQtq9rqagvsL5a1ZfPgEEo7uZ6KTdfdcZXM0FhzzP8DaevYP5oF-jrezLP7GS5w4j8wZDS16tCTTDD14upA8MgZAUlYk5uy95GI4-3lDzuu223ym7u0Et5xMZWA3VThSocD324p~QIKKxiRP3HIF9cc~SB79KbMMJjOCmqkxajzDOVKK~iqvPgBoqVGPW2uz8llvQqQ1F4~gZLXAG-JWomrmPfAqQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TFS of 449 patients with CLL according to the sFLC assay. Kaplan-Meier curves show the 3-year probability of remaining treatment-free for CLL cases subdivided into 3 groups based on their normal [normal sFLC(κ/λ)] or abnormal κ or λ sFLC ratio. The 3-year TFS was significantly lower in patients with κ or λ sFLC(κ/λ).
